|Last Updated: December 7, 2021 @ 10:13 am|
|Stability:||Ambient: 5 Day(s); Refrigerated: 14 Day(s); Frozen: 3 Month(s); Incubated: Unacceptable|
|Interpretive Data:||General Reference Range : 0-37.0 U/mL|
The Roche e801 CA 19-9 electrochemiluminescent immunoassay is used. Results obtained with different assay methods or kits cannot be used interchangeably. CA 19-9 is useful in monitoring pancreatic, hepatobiliary, gastric, hepatocellular, and colorectal cancer. The CA 19-9 assay value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date.
Updated test information can only be guaranteed by using this website.